Clinical experience with omalizumab in a Portuguese severe asthma unit;Experiência clínica com omalizumab na consulta de asma grave

Revista Portuguesa de Pneumologia

Volumn 20, Issue 2, 2014, Pages 78-83

  Alfarrobaa, S ^a   Videiraa, W ^a   Galvao Lucasa C ^a   Carvalhob, F ^a   Barbaraa C ^a  

^a HOSPITAL PULIDO VALENTE   (Portugal)

Author keywords

Anti IgE; Asthma; Omalizumab

Indexed keywords

GLUCOCORTICOID; OMALIZUMAB; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; LUNG FUNCTION; RETROSPECTIVE STUDY; SEVERE ASTHMA; TREATMENT DURATION; FEMALE; HOSPITAL SUBDIVISIONS AND COMPONENTS; MALE; MIDDLE AGED; PORTUGAL; SEVERITY OF ILLNESS INDEX;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; FEMALE; HOSPITAL UNITS; HUMANS; MALE; MIDDLE AGED; PORTUGAL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84904537143     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rppneu.2013.07.006     Document Type: Article

References (8)

1. The global strategy for asthma management and prevention, Global Initiative for Asthma (GINA) 2011. Global Initiative for Asthmawebsite. [consultado 21 Jan 2011]. Disponível em: http://www.ginasthma.org
2. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;603:309-16
3. Miller CW, Krishnaswamy N, Johnston C, Krishnaswamy G. Severe asthma and the omalizumab option. Clin Mol Allergy. 2008; 6:4.
4. Hanania NA. Targeting airway inflammation in asthma: Current and future therapies. Chest. 2008;133:989-98
5. Yegin A, Eisner M, Trzaskoma B, Chen H. Impact of omalizumab treatment on concomitant asthma medications in patients with moderate-to-severe allergic asthma. Chest. 2011;140:282A.
6. Boushey Jr HA. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol. 2001;108 2Suppl:S77-83
7. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001;164 8 Pt 2:S12-7
8. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA,Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59-99.